Clinical trial • Phase III • Other
Midazolam for Breech (podalic) or transverse fetal presentation (dystocic fetal presentation)
Phase III trial of Midazolam for Breech (podalic) or transverse fetal presentation (dystocic fetal presentation).
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Breech (podalic) or transverse fetal presentation (dystocic fetal presentation)
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 20-08-2024
- First CTIS Authorization Date
- 30-09-2024
Trial design
Randomised, open-label, groupe contrôle: 0.10 mg/kg midazolam, sublingual; groupe intervention: spinal (rachianesthesia) with 10 mg bupivacaine administered intrathecally using a 25 gauge needle in sitting position, aseptic technique.-controlled Phase III trial across 1 site in France.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Groupe contrôle: 0.10 mg/kg midazolam, sublingual; Groupe intervention: spinal (rachianesthesia) with 10 mg bupivacaine administered intrathecally using a 25 gauge needle in sitting position, aseptic technique.
- Target Sample Size
- 200
Eligibility
Recruits 200 Patients deprived of liberty or under legal protection (guardianship or curatorship) and patients unable to read or write are excluded; signed informed consent from the patient is required..
- Vulnerable Population
- Patients deprived of liberty or under legal protection (guardianship or curatorship) and patients unable to read or write are excluded; signed informed consent from the patient is required.
Inclusion criteria
- {"criterion_text":"- Age ≥ 18 years\n- Patient presenting with a dystocic (podalic or transverse) fetus at 36 weeks' gestation\n- Patient covered by a social insurance system\n- Signed informed consent"}
Exclusion criteria
- {"criterion_text":"- Obstetrical contraindications : - Placenta previa ; - 3rd trimester metrorrhagia; - Suspicion of foetal anoxia; - Patient who has already had more than one caesarean section; - Twin pregnancies; - HIV+; - Anticoagulant treatment in progress\n- Anaesthetic contraindications : - Infection at the puncture site, generalised infection or severe septic state; - Intracranial hypertension; - Uncompensated heart failure; - Constitutive or acquired coagulation anomalies, including curative anticoagulant treatments; - Neuropathy with demyelination of nerve fibres in advanced stages or in the process of unstabilised recovery; - Syringomyelia\n- Patient deprived of liberty, under legal protection (guardianship or curatorship), unable to read or write."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Successful EMV once the procedure has been completed, i.e. a foetus in cephalic presentation.","definition_or_measurement_approach":"Defined as obtaining a foetus in cephalic presentation once the external cephalic version procedure has been completed."}
Secondary endpoints
- {"endpoint_text":"- Events secondary to the procedure: caesarean section for permanent bradycardia, retroplacental haematoma, rupture of membranes","definition_or_measurement_approach":"Occurrence of procedure-related events including caesarean section for permanent fetal bradycardia, retroplacental haematoma, and rupture of membranes."}
- {"endpoint_text":"- Events secondary to the anaesthetic: hypotension, bradycardia, desaturation, nausea/vomiting, number of punctures greater than 11 (failure of the first spinal puncture and need for one or more others)","definition_or_measurement_approach":"Occurrence of anaesthesia-related adverse events (hypotension, bradycardia, desaturation, nausea/vomiting) and count of punctures; number of punctures > 11 considered as failure of first spinal puncture."}
- {"endpoint_text":"- The pain felt by the patient: assessed by VAS","definition_or_measurement_approach":"Patient-reported pain measured using the visual analogue scale (VAS/EVA)."}
- {"endpoint_text":"- Final route of delivery","definition_or_measurement_approach":"Recorded final mode of delivery (vaginal/natural route or caesarean section)."}
- {"endpoint_text":"- Presentation at delivery","definition_or_measurement_approach":"Recorded fetal presentation at delivery (cephalic or podalic)."}
Recruitment
- Planned Sample Size
- 200
- Recruitment Window Months
- 102
- Consent Approach
- Signed informed consent required from the patient. Subject information and informed consent forms are listed (L1_SIS_PATIENT, L1_ICF_PATIENT). No minors included; consent provided by the adult patient. Documentation available in French (translations present).
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 200
France
- Latest Decision Or Authorization Date
- 30-09-2024
- Number Of Sites
- 1
- Number Of Participants
- 200
Sites
- Site Name
- Centre Hospitalier Universitaire Amiens Picardie
- Department Name
- service de gynécologie - obstétrique – orthogénie
- Principal Investigator Name
- Arthur FOULON
- Principal Investigator Email
- foulon.arthur@chu-amiens.fr
- Contact Person Name
- Arthur FOULON
- Contact Person Email
- foulon.arthur@chu-amiens.fr
- Number Of Participants
- 200
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire Amiens Picardie
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Midazolam 1 mg/ml Solution for Injection or Infusion
- Active Substance
- Midazolam
- Modality
- Small molecule
- Routes Of Administration
- sublingual (as per arm description); product form listed as solution for injection/infusion
- Route
- sublingual
- Authorisation Status
- Authorised (marketing authorisation PL 20075/0080)
- Starting Dose
- 0.10 mg/kg (sublingual)
- Maximum Dose
- 0.10 mg/kg
- Investigational Product Name
- BUPIVACAINE VIATRIS 20 mg/4 ml, solution injectable pour voie intra rachidienne en ampoule
- Active Substance
- Bupivacaine hydrochloride (anhydrous)
- Modality
- Small molecule
- Routes Of Administration
- intrathecal injection (rachianesthesia)
- Route
- intrathecal (injection)
- Authorisation Status
- Authorised (marketing authorisation 3400956311651)
- Starting Dose
- 10 mg intrathecal (rachianesthesia)
- Maximum Dose
- 10 mg
Related trials
Other published trials that may interest you.